Holen Sie sich die Stockscreener-App
5.77
0.87%
0.05
Handel nachbörslich:
5.77
Schlusskurs vom Vortag:
$5.72
Offen:
$5.73
24-Stunden-Volumen:
5.26M
Relative Volume:
4.99
Marktkapitalisierung:
$427.48M
Einnahmen:
$531.00K
Nettoeinkommen (Verlust:
$-99.96M
KGV:
-2.6324
EPS:
-2.1919
Netto-Cashflow:
$-98.96M
1W Leistung:
+9.49%
1M Leistung:
-15.77%
6M Leistung:
-10.82%
1J Leistung:
+147.11%
1-Tages-Spanne:
$5.535
$5.95
1-Wochen-Bereich:
$5.21
$6.0736
52-Wochen-Spanne:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.77 | 423.78M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
[144] Lexeo Therapeutics, Inc. SEC Filing - stocktitan.net
If You Invested $1,000 in Lexeo Therapeutics Inc (LXEO) - stocktitan.net
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
LXEO Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-04-02 23:43:24 - baoquankhu1.vn
LXEO Earnings History & Surprises | EPS & Revenue Results | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating - Investing.com
Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases - Minichart
Big Picture: Should I invest in Lexeo Therapeutics Inc before earnings2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Lexeo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks
Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results - MarketBeat
Lexeo Therapeutics | 10-K: Annual report - Moomoo
Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - stocktitan.net
Lexeo Therapeutics : Corporate Presentation March 2026 - marketscreener.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill
US Market Wrap: Is Lexeo Therapeutics Inc on track to beat earnings2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan
Aug Mood: Will Lexeo Therapeutics Inc outperform its industry peers2026 Action & Capital Efficient Trading Techniques - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - msn.com
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - stocktitan.net
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Published on: 2026-03-07 09:09:20 - baoquankhu1.vn
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - The Manila Times
Genetic medicine firm Lexeo to stream Leerink conference chat - stocktitan.net
Nasdaq Moves: Can Lexeo Therapeutics Inc ride the EV waveRate Cut & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference - MarketBeat
Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
LXEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Update: Is Lexeo Therapeutics Inc forming a bullish divergenceProduct Launch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Profit Review: Is Lexeo Therapeutics Inc forming a bullish divergenceShare Buyback & Risk Controlled Stock Alerts - baoquankhu1.vn
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Feb 18 '26 |
Sale |
6.38 |
10,173 |
64,924 |
392,483 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):